ZYBT

Zhengye Biotechnology Holding Ltd

Jun 04 • 04:00PM ET

0.8300

+0.0288 3.59 %

Healthcare • Drug Manufacturers - Specialty & Generic • China • Nano • NASD

Jun 04, 4:10 PMZhengye Biotechnology gets Nasdaq notice it is below $1.00 minimum bid price, has until Nov. 25, 2026 to regain compliance

Peers: INCR ANIK LFCR TKNO DERM OGI ASRT CRDL OPTH ACB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.21	Insider Own	74.06%	Shs Outstand	29.73M	Perf Week	2.46%
Market Cap	24.68M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	7.71M	Perf Month	-4.60%
Enterprise Value	36.13M	PEG	-	EPS next Q	-	Inst Own	0.41%	Short Float	0.44%	Perf Quarter	6.41%
Income	-9.74M	P/S	1.53	EPS this Y	-	Inst Trans	-24.25%	Short Ratio	0.15	Perf Half Y	-61.57%
Sales	16.18M	P/B	1.10	EPS next Y	-	ROA	-14.98%	Short Interest	0.03M	Perf YTD	-27.83%
Book/sh	0.75	P/C	3.32	EPS next 5Y	-	ROE	-26.09%	52W High	13.08 -93.65%	Perf Year	-87.09%
Cash/sh	0.25	P/FCF	14.26	EPS past 3/5Y	- -	ROIC	-26.28%	52W Low	0.68 22.06%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-25.18% -16.43%	Gross Margin	20.41%	Volatility	7.55% 9.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.23	EPS Y/Y TTM	-717.42%	Oper. Margin	-60.73%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.80	Sales Y/Y TTM	-37.53%	Profit Margin	-60.22%	RSI (14)	43.42	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	1.14	EPS Q/Q	-2195.59%	SMA20	-7.11%	Beta	-2.34	Target Price	-
Payout	-	Debt/Eq	0.30	Sales Q/Q	-40.44%	SMA50	-10.32%	Rel Volume	0.02	Prev Close	0.80
Employees	269	LT Debt/Eq	0.04	Earnings	-	SMA200	-65.40%	Avg Volume	221.54K	Price	0.83
IPO	Jan 07, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	4,244	Change	3.59%

Jun-04-26 04:05PM	Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Apr-28-26 04:30PM	Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results (PR Newswire) -5.69%
Apr-06-26 09:25AM	Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure (GlobeNewswire)
Feb-10-26 08:30AM	Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders (GlobeNewswire)
Jul-03-25 08:30AM	Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results (PR Newswire)
04:05PM	Loading…
May-23-25 04:05PM	Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F (GlobeNewswire) -12.33%
Jan-14-25 12:00PM	Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option (GlobeNewswire)
Jan-08-25 12:00PM	Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering (GlobeNewswire) -7.41%
Jan-06-25 05:50PM	Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering (GlobeNewswire)

Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. It offers a range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company was founded on March 24, 2023 and is headquartered in Jilin City, China.

Co-Chief Executive OfficerMr. Songlin Song

Chief Financial OfficerMr. Ping Wang

Chief Operating OfficerMr. Zhongyao Liu

Vice General ManagerMs. Yuhong Cheng

Co-Chief Executive OfficerMr. Aiden Han

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vanguards Skyline Holdings Lim	Shareholder	Nov 01 '25	Proposed Sale	12.91	2,278,752	29,419,666		Oct 22 04:10 PM
VVAX Holdings Limited	Shareholder	Nov 01 '25	Proposed Sale	2.62	684,996	1,794,690		Oct 22 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZYBT

Zhengye Biotechnology Holding Ltd

Upgrade your Finviz experience